JP2015527341A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015527341A5 JP2015527341A5 JP2015525570A JP2015525570A JP2015527341A5 JP 2015527341 A5 JP2015527341 A5 JP 2015527341A5 JP 2015525570 A JP2015525570 A JP 2015525570A JP 2015525570 A JP2015525570 A JP 2015525570A JP 2015527341 A5 JP2015527341 A5 JP 2015527341A5
- Authority
- JP
- Japan
- Prior art keywords
- lung cancer
- histology
- cetuximab
- determining
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2012/079399 | 2012-07-31 | ||
| CN2012079399 | 2012-07-31 | ||
| PCT/US2013/053091 WO2014028221A1 (en) | 2012-07-31 | 2013-07-31 | Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015527341A JP2015527341A (ja) | 2015-09-17 |
| JP2015527341A5 true JP2015527341A5 (enExample) | 2016-07-07 |
| JP6324381B2 JP6324381B2 (ja) | 2018-05-16 |
Family
ID=50101405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525570A Expired - Fee Related JP6324381B2 (ja) | 2012-07-31 | 2013-07-31 | 抗ｅｇｆｒ薬物による処置のための非小細胞肺癌患者を同定するための組織学的マーカー |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9921222B2 (enExample) |
| EP (1) | EP2879712B1 (enExample) |
| JP (1) | JP6324381B2 (enExample) |
| CN (1) | CN104168921B (enExample) |
| ES (1) | ES2668861T3 (enExample) |
| WO (1) | WO2014028221A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017527627A (ja) * | 2014-09-16 | 2017-09-21 | アッヴィ・インコーポレイテッド | 喫煙者における非小細胞肺癌の治療のための、カルボプラチンおよびパクリタキセルと併用したベリパリブ |
| CN110520543A (zh) | 2017-03-29 | 2019-11-29 | 中美冠科生物技术（太仓）有限公司 | 确定胃癌对西妥昔单抗敏感性的系统和方法 |
| CN112813164A (zh) * | 2021-01-18 | 2021-05-18 | 四川省肿瘤医院 | Ereg促进nsclc细胞对egfr-tki产生耐药性原因的验证方法 |
| CN115810399A (zh) * | 2022-11-14 | 2023-03-17 | 南京工业大学 | 一种基于转录模式的肺腺癌组织学亚型分类方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5942602A (en) | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| EP2110138A1 (en) | 1999-08-27 | 2009-10-21 | Genentech, Inc. | Dosages for treatment of anti-erbB2 antibodies |
| EP1622941A2 (en) | 2003-03-20 | 2006-02-08 | ImClone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
| ES2387809T3 (es) | 2004-03-19 | 2012-10-02 | Imclone Llc | Anticuerpo frente al receptor del factor de crecimiento epidérmico humano |
| SI1913157T2 (sl) | 2005-06-28 | 2017-02-28 | Genentech, Inc. | EGFR in KRAS mutacije za napoved bolnikovega odziva na zdravljenje z EGFR inhibitorjem |
| JP2009515878A (ja) | 2005-11-12 | 2009-04-16 | イーライ リリー アンド カンパニー | 抗ｅｇｆｒ抗体 |
| AU2007353412A1 (en) | 2006-11-21 | 2008-11-20 | Fox Chase Cancer Center | Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof |
| US7977336B2 (en) | 2006-12-28 | 2011-07-12 | Banyu Pharmaceutical Co. Ltd | Aminopyrimidine derivatives as PLK1 inhibitors |
| KR100968591B1 (ko) | 2007-06-14 | 2010-07-08 | 한국과학기술연구원 | 약물전달용 폴리포스파젠계 하이드로젤, 그의 제조방법 및그의 용도 |
| US20100009390A1 (en) | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Mutant antibodies with high affinity for egfr |
| KR20110047255A (ko) | 2008-09-26 | 2011-05-06 | 로슈 글리카트 아게 | 이중특이적 항-ｅｇｆｒ／항-ｉｇｆ-１ｒ 항체 |
| WO2010080463A1 (en) | 2008-12-18 | 2010-07-15 | Imclone Llc | Antibody humanization |
| KR101108642B1 (ko) | 2009-09-29 | 2012-02-09 | 주식회사 녹십자 | 표피 성장 인자 수용체에 특이적으로 결합하는 항체 |
| US8658175B2 (en) | 2009-10-28 | 2014-02-25 | Abbvie Biotherapeutics Inc. | Anti-EGFR antibodies and their uses |
| US20110118298A1 (en) * | 2009-11-13 | 2011-05-19 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| US20110158987A1 (en) | 2009-12-29 | 2011-06-30 | F. Hoffmann-Laroche Ag | Novel antibody formulation |
| JP2011144124A (ja) | 2010-01-13 | 2011-07-28 | Fujirebio Inc | 活性型ｅｇｆｒ特異抗体 |
| WO2011140151A1 (en) | 2010-05-04 | 2011-11-10 | Dyax Corp. | Antibodies against epidermal growth factor receptor (egfr) |
| WO2011140254A1 (en) | 2010-05-04 | 2011-11-10 | Adimab, Llc | Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
| US9029513B2 (en) | 2010-06-04 | 2015-05-12 | Toagosei Co. Ltd. | Anti-EGFR antibody and use thereof |
| WO2011156617A2 (en) | 2010-06-09 | 2011-12-15 | Aveo Pharmaceuticals, Inc. | Anti-egfr antibodies |
| BR112013003257A2 (pt) | 2010-08-10 | 2016-06-14 | Glycotope Gmbh | anticorpos egfr humanizados. |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
-
2013
- 2013-07-31 US US14/418,684 patent/US9921222B2/en not_active Expired - Fee Related
- 2013-07-31 WO PCT/US2013/053091 patent/WO2014028221A1/en not_active Ceased
- 2013-07-31 EP EP13829184.4A patent/EP2879712B1/en active Active
- 2013-07-31 ES ES13829184.4T patent/ES2668861T3/es active Active
- 2013-07-31 JP JP2015525570A patent/JP6324381B2/ja not_active Expired - Fee Related
- 2013-07-31 CN CN201380015223.9A patent/CN104168921B/zh not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Singh et al. | TNBC: potential targeting of multiple receptors for a therapeutic breakthrough, nanomedicine, and immunotherapy | |
| Tsimberidou et al. | Precision cancer medicine: the future is now, only better | |
| JP2014514278A5 (enExample) | ||
| Aggarwal et al. | Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy | |
| WO2010145796A3 (en) | Biomarkers and methods for determining efficacy of anti-egfr antibodies in cancer therapy | |
| JOP20140128B1 (ar) | تركيبة علاجية تشتمل على مثبط b_raf ومثبط ثان | |
| WO2018183817A3 (en) | Tumor burden as measured by cell free dna | |
| JP2016515141A5 (enExample) | ||
| JP2015505959A5 (enExample) | ||
| JP2015210268A5 (enExample) | ||
| Habib et al. | Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: a retrospective study | |
| Quaquarini et al. | Prognostic and predictive roles of HER2 status in non-breast and non-gastroesophageal carcinomas | |
| Kotake et al. | Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial) | |
| Lee et al. | Composition of inflammatory cells regulating the response to concurrent chemoradiation therapy for HPV (+) tonsil cancer | |
| Shao et al. | Use and misuse of waterfall plots | |
| Hyung et al. | Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysis | |
| JP2019519772A (ja) | Ｈｅｒ２及びｈｅｒ３の経路サブタイピングに基づく乳癌患者の薬物療法の選択方法 | |
| WO2016161153A3 (en) | Prognostic and diagnostic methods for colorectal cancer | |
| JP6324381B2 (ja) | 抗ｅｇｆｒ薬物による処置のための非小細胞肺癌患者を同定するための組織学的マーカー | |
| WO2014023808A3 (en) | Method for evaluating a cancer patient for propensity to respond to a therapy | |
| Sidaway | WEE1 kinase inhibitor shows promise | |
| Killock | Personalized MRD assays and therapy? | |
| Hirsch et al. | Quality of Care of Patients With Non–Small-Cell Lung Cancer: A Report of a Performance Improvement Initiative | |
| Masago et al. | Minimal residual disease after radical surgery in EGFR-mutant non-small cell lung cancer | |
| Tabernero et al. | P-38 KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma |